Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study
Open Access
- 21 February 2024
- journal article
- research article
- Published by BMJ in BMJ Medicine
- Vol. 3 (1) , e000408
Abstract
Objective: To determine the balance of costs, risks, and benefits for different thromboprophylaxis strategies for medical patients during hospital admission. Design: Decision analysis modelling study. Setting: NHS hospitals in England. Population: Eligible adult medical inpatients, excluding patients in critical care and pregnant women. Interventions: Pharmacological thromboprophylaxis (low molecular weight heparin) for all medical inpatients, thromboprophylaxis for none, and thromboprophylaxis given to higher risk inpatients according to risk assessment models (Padua, Caprini, IMPROVE, Intermountain, Kucher, Geneva, and Rothberg) previously validated in medical cohorts. Main outcome measures: Lifetime costs and quality adjusted life years (QALYs). Costs were assessed from the perspective of the NHS and Personal Social Services in England. Other outcomes assessed were incidence and treatment of venous thromboembolism, major bleeds including intracranial haemorrhage, chronic thromboembolic complications, and overall survival. Results: Offering thromboprophylaxis to all medical inpatients had a high probability (>99%) of being the most cost effective strategy (at a threshold of £20 000 (€23 440; $25 270) per QALY) in the probabilistic sensitivity analysis, when applying performance data from the Padua risk assessment model, which was typical of that observed across several risk assessment models in a medical inpatient cohort. Thromboprophylaxis for all medical inpatients was estimated to result in 0.0552 additional QALYs (95% credible interval 0.0209 to 0.1111) while generating cost savings of £28.44 (−£47 to £105) compared with thromboprophylaxis for none. No other risk assessment model was more cost effective than thromboprophylaxis for all medical inpatients when assessed in deterministic analysis. Risk based thromboprophylaxis was found to have a high (76.6%) probability of being the most cost effective strategy only when assuming a risk assessment model with very high sensitivity is available (sensitivity 99.9% and specificity 23.7% v base case sensitivity 49.3% and specificity 73.0%). Conclusions: Offering pharmacological thromboprophylaxis to all eligible medical inpatients appears to be the most cost effective strategy. To be cost effective, any risk assessment model would need to have a very high sensitivity resulting in widespread thromboprophylaxis in all patients except those at the very lowest risk, who could potentially avoid prophylactic anticoagulation during their hospital stay.Keywords
Funding Information
- Health Technology Assessment Programme (NIHR127454)
This publication has 54 references indexed in Scilit:
- Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT studyBMJ Open, 2013
- Variations in risk assessment models may contribute to the existing gap between venous thromboembolism prophylaxis guidelines and adherenceSpringerPlus, 2012
- Risk factor model to predict venous thromboembolism in hospitalized medical patientsJournal of Hospital Medicine, 2011
- Reliability of a point‐based VTE risk assessment tool in the hands of medical residentsJournal of Hospital Medicine, 2011
- The responsiveness and validity of the CAMPHOR Utility IndexEuropean Respiratory Journal, 2008
- Long term survival after primary intracerebral haemorrhage: a retrospective population based studyJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Relation between quality of anticoagulant treatment and the development of the postthrombotic syndromeJournal of Thrombosis and Haemostasis, 2005
- Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory diseaseAmerican Heart Journal, 2003
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999
- Automated Computer Interviews to Elicit Utilities: Potential Applications in the Treatment of Deep Venous ThrombosisJournal of the American Medical Informatics Association, 1997